SavedAdd your journal

Journals / Eurasian Journal of Medicine and Oncology / 2020 / Cilt: 4 - Sayı: 3

The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2

Rohan R. NARKHEDE
Rameshwar S. CHEKE
Jaya P AMBHORE
Sachin D.SHİNDE
Pages
185–195
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: From this study, we can be suggested that these drugs are promising candidates for antiviral treatment with high potential to fight specially against SARS-CoV-2 strain.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The novel human coronavirus which has been designated as SARS-CoV-2 was firstly emerged in late 2019 in Wuhan, China causing respiratory illness called COVID-19.
📊
Key Findings & Data:In view of the potential threat of epidemic, scientists around the world have been running to understand SARS-CoV-2 and investigate the pathophysiology of this disease to find out potential treatment and discover effective therapeutic drug candidate.
💡
Conclusion & Impact:Conclusion: From this study, we can be suggested that these drugs are promising candidates for antiviral treatment with high potential to fight specially against SARS-CoV-2 strain.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: The novel human coronavirus which has been designated as SARS-CoV-2 was firstly emerged in late 2019 in Wuhan, China causing respiratory illness called COVID-19. This virus has spread rapidly around the globe. In view of the potential threat of epidemic, scientists around the world have been running to understand SARS-CoV-2 and investigate the pathophysiology of this disease to find out potential treatment and discover effective therapeutic drug candidate. The disorder caused due to the outbreak of coronavirus is an intense need for the development of potential agents against the SARS-CoV-2. Methods: In this study, we have measured the virtual interaction of COVID-19 main protease in complex with an inhibitor N3 (PDB ID 6LU7) with antiviral and antimalarial drug as well as SARS Spike glycoprotein-Human ACE2 complex (PDB ID 6CS2) with antimalarial drugs currently in the market using the AutoDockVina suite. Results: The binding energies obtained from the docking of 6LU7 with ligand, oseltamivir, ritonavir, remdesivir, ribavirin, favipiravir, chloroquine and hydroxychloroquine were found to be -4.7, -7.3, -6.5, -5.6, -5.4, -5.1, -5.3, kcal/mol, respectively. Similarly the binding energies obtained from the docking of 6CS2 with ligand, chloroquine and hydroxychloroquine were -7.1 and -6.8kcal/mol. The docking result suggest a higher affinity of the drug molecule such as oseltamivir, ritonavir, remdesivir, ribavirin, favipiravir, against SARS-CoV-2 since they attributed high affinity interactions withCOVID-19 main protease in complex with an inhibitor N3. In addition, chloroquine and hydroxychloroquine show prominent binding interaction with SARS Spike glycoprotein-Human ACE2 complex. Conclusion: From this study, we can be suggested that these drugs are promising candidates for antiviral treatment with high potential to fight specially against SARS-CoV-2 strain.

🔖

Cite This Article

NARKHEDE, R. R., CHEKE, R. S., AMBHORE, J. P., D.SHİNDE, S. (2020). The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2. Eurasian Journal of Medicine and Oncology, Cilt: 4 - Sayı: 3, 185–195. https://ajindex.com/articles/125146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3
  2. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet 2020;395:470– 3
  3. Coronavirus disease 2019 https://www.who.int/emergencies/ diseases/novel-coronavirus-2019 Accessed: 2020-04-14
  4. Mcconkey B, Sobolev V, Edelman M. The performance of current methods in ligand-protein docking. Curr Sci;83
  5. Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303:1813–8
  6. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov 2002;1:882–94
  7. Langer T, Hoffmann RD. Virtual screening: an effective tool for lead structure discovery? Curr Pharm Des 2001;7:509–527
  8. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004;3:935–949
  9. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature reviews. Drug discovery 2020;19:149–50
  10. Lim J, Jeon S, Shin HY, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RTPCR. J Korean Med Sci 2020;35:e79
  11. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020;382:929–36
  12. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–71
  13. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis an Off Publ Infect Dis Soc Am [Epub ahead of print]
  14. Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) 2015;795–104
  15. Jin Z, Du X, Xu Y, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature [Epub ahead of print]
  16. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020;105938
  17. Kirchdoerfer RN, Wang N, Pallesen J, et al. Stabilized coronavirus spikes are r